Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $33.69 down -0.44% from its previous closing price of $33.84. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 2.39 million shares were traded.
Ratios:
For a deeper understanding of BridgeBio Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 19 ’25 when NEIL KUMAR bought 26,156 shares for $33.84 per share.
KKR Genetic Disorder L.P. sold 6,000,000 shares of BBIO for $205,200,000 on May 12 ’25. The 10% Owner now owns 13,260,971 shares after completing the transaction at $34.20 per share. On May 12 ’25, another insider, KKR Genetic Disorder L.P., who serves as the Affiliate of the company, bought 6,000,000 shares for $35.68 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 50.20.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $39.54, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -2.17%, while the 200-Day Moving Average is calculated to be 13.23%.
Shares Statistics:
A total of 189.83M shares are outstanding, with a floating share count of 160.65M. Insiders hold about 15.40% of the company’s shares, while institutions hold 85.69% stake in the company.
